Data from four Phase 3 trials of faricimab, an experimental bispecific antibody for two eye diseases, were published online in The Lancet on 24 January, showing that the treatment delivered vision gains for patients that were at least as good as those achieved for aflibercept (Eylea), a widely prescribed ocular treatment. At the same time, faricimab required less frequent injections, according to the studies. Two of the trials enrolled patients with wet age-related macular degeneration and two enrolled patients with diabetic macular oedema.
